AMX0035 in the treatment of amyotrophic lateral sclerosis: a scoping review
DOI:
https://doi.org/10.34024/rnc.2023.v31.15044Keywords:
Amyotrophic Lateral Sclerosis, Riluzole, Drug Therapy, Respiration-artificial, Sodium phenylbutyrate and taurursodiolAbstract
Objective. To carry out a scope review on the effects of using the drug AMX0035, compared to Riluzole, for the treatment and reduction of the need for mechanical ventilation in patients with amyotrophic lateral sclerosis (ALS). Method. The Population/Patient/Problem, Intervention, Control/Comparison, Outcome (PICO) methodology was used as a guiding mechanism for elaborating the problem-question, supporting the search for articles in the SCIELO, BVS, MEDLINE and LILACS databases, selecting, through the exclusion and inclusion criteria united with Boolean operators, the articles targeted later, being sent to the extraction process. Results. 3 articles were selected that used randomized control tests and phase II clinical trials to weigh safety and efficacy of sodium phenylbutyrate - taurursodiol in a patient with ALS. In both, it was demonstrated that the use of medication significantly reduced the effects of the disease on the functional activities of the patients according to the ALSFRS scale, in addition to verifying that the plasmatic concentrations of heavy subunits of phosphorylated neurofilaments were lower in the groups that received the placebo. It was also noted that, in this same group, the cumulative risk of death, tracheostomy or hospitalization was higher. Conclusion. The use of AMX0035 proved to be effective in improving the clinical condition of patients with ALS, but studies and research are still needed in order to prove its validity and ensure the minimum of possible adverse effects.
Metrics
References
Associação Brasileira de Esclerose Lateral Amiotrófica (AbrELA). Uma breve história da ELA. Classificação e quadro clínico, Diagnóstico, Epidemiologia, Etiologia, Tratamento, Orientação terapêutica sugerida. Esclerose Lateral Amiotrófica. São Paulo: AbrELA; 2013. https://www.abrela.org.br/wp-content/uploads/2018/05/AbrELA_LIVRETO_web.pdf
van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet 2017;390:2084-98. https://doi.org/10.1016/S0140-6736(17)31287-4
D’Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Rad Biol Med 2013;65:509-27. https://doi.org/10.1016/j.freeradbiomed.2013.06.029
Saccon RA, Bunton-Stasyshyn RKA, Fisher EMC, Fratta P. Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain 2013;136:2342-58. https://doi.org/10.1093/brain/awt097
Wang SJ, Wang KY, Wang WC. Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 2004;125:191-201. https://doi.org/10.1016/j.neuroscience.2004.01.019
Kruman II, Pedersen WA, Springer JE, Mattson MP. ALS-Linked Cu/Zn–SOD Mutation Increases Vulnerability of Motor Neurons to Excitotoxicity by a Mechanism Involving Increased Oxidative Stress and Perturbed Calcium Homeostasis. Exp Neurol 1999;160:28-39. https://doi.org/10.1006/exnr.1999.7190
Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis. New Eng J Med 2020;383:919-30. https://doi.org/10.1056/NEJMoa1916945
Paganoni S, Berry JD, Quintana M, Macklin E, Saville BR, Detry MA, et al. Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development. Ann Neurol 2022;91:165-75. https://doi.org/10.1002/ana.26285
Miller R. Riluzole for ALS: what is the evidence? Amyotrop Lat Scler Other Motor Neuron Dis 2003;4:135-5. https://doi.org/10.1080/14660820310012628
Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Infor Libr J 2009;26:91-108. https://doi.org/10.1111/j.1471-1842.2009.00848.x
Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic Review or Scoping review? Guidance for Authors When Choosing between a Systematic or Scoping Review Approach. BMC Med Res Methodol 2018;18:143. https://doi.org/10.1186/s12874-018-0611-x
Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med 2018;169:467-73. https://doi.org/10.7326/M18-0850
Oliveira Araújo WC. Recuperação da informação em saúde. ConCI 2020;3:100-34. https://doi.org/10.33467/conci.v3i2.13447
Paganoni S, Hendrix S, Dickson SP, Knowlton N, Macklin EA, Berry JD, et al. Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taururs odiol in amyotrophic lateral sclerosis. Muscle Nerve 2021;63:31-9. https://doi.org/10.1002/mus.27091
Paganoni S, Hendrix S, Dickson SP, Knowlton N, Berry JD, Elliott MA, et al. Effect of sodium phenylbutyrate/taururso diol on tracheostomy/ventilatio n-free survival and hospitalisation in amyotrophic lateral sclerosis: long- term results from the CENTAUR trial. J Neurol Neurosurg Psychiatry 2022;93:871-5. https://doi.org/10.1136/jnnp-2022-329024
Sociedade Brasileira de Profissionais em Pesquisa Clínica (SBPPC). (internet). Disponível em: https://www.sbppc.org.br/fases-de-uma-pesquisa-clinica
Guedes K, Pereira C, Pavan K, Valério BCO. Cross-cultural adaptation and validation of als Functional Rating Scale-Revised in Portuguese language. Arq Neuropsiqu 2010;68:44-7. https://doi.org/10.1590/s0004-282x2010000100010
Gomes CMS, Zuqui AC, Schiavo KV, Oliveira JFP. Funcionalidade e qualidade de vida de pessoas com esclerose lateral amiotrófica e percepção da sobrecarga e apoio social de cuidadores informais. Acta Fisiatr 2021;27:167-73. https://doi.org/10.11606/issn.2317-0190.v27i3a172216
Santos A, Prudente C. Relação entre Capacidade Funcional e Qualidade de Vida de pacientes com Esclerose Lateral Amiotrófica. Anais do II Congresso de Ciência e Tecnologia da PUC Goiás - 2016. Disponível em: http://www2.pucgoias.edu.br/ucg/prope/pesquisa/anais/2016/PDF/XVII_JORNADA_INICIACAO_CIENTIFICA/anais-2congresso-ct2016-inicientifica.328.pdf
Institute for Clinical and Economic Review (ICER). AMX0035 and Oral Edaravone for Amyotrophic Lateral Sclerosis Evidence Report. 2022. https://icer.org/wp-content/uploads/2022/02/ICER_ALS_Evidence-Report_080422.pdf
Orsini M, França Júnior MC, Freitas MRG, Ribeiro P, Sant'Anna Junior M, Lopes ML, et al. Esclerose Lateral Amiotrófica: novas possibilidades terapêuticas em um arcabouço fisiopatológico ainda em construção. Rev Bras Neurol 2017;53:27-37. https://doi.org/10.46979/rbn.v53i4.14637
Linden Junior E, Linden D, Mathia GB, Brol AM, Heller P, Traverso MED, et al. Esclerose Lateral Amiotrófica:artigo de atualização. Fisioter Ação 2016;(Ann eletr):47-62. https://periodicos.unoesc.edu.br/fisioterapiaemacao/article/view/10241
Amorim DSR. A Terapêutica da Dor Neuropática em Portugal: Proposta de uma Linha Orientadora de Uniformização (Dissertação). Lisboa: Universidade de Lisboa, 2012. https://repositorio.ul.pt/bitstream/10451/11309/1/A%20Terap%C3%AAutica%20da%20dor%20Neurop%C3%A1tica%20em%20Portugal%20Proposta%20de%20uma%20Linha%20Orientadora%20de%20Uniformiza%C3%A7%C3%A3p.pdf
Albuquerque KMF, Pernambuco L, Lopes LW. Impacto do tratamento medicamentoso na voz, fala e deglutição de pacientes com esclerose lateral amiotrófica: revisão sistemática. Audiol Comm Res 2022;27:1-9. https://doi.org/10.1590/2317-6431-2021-2599
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Karolyna de Oliveira Ramos, Luciano Francisco de Luna Júnior, Luiz Eduardo Cruz Soares, Maíra Espíndola Torres, Paulo Gabriel Soares da Silva, Pedro Victor de Brito Cordeiro, Sérgio Roberto Fernandes Maciel, Ygor Falcão Gomes Mendes, Hugo Rafael de Souza e Silva
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
Accepted 2023-06-07
Published 2023-07-05
